Locus's therapy combines six phages, including engineered CRISPR phages, to selectively target and degrade E. coli DNA, effectively treating UTIs.
The clinical trial showed that within four hours of treatment, E. coli levels in urine fell significantly, leading to resolution of UTI symptoms in participants.
CEO Paul Garofolo emphasizes the precision of their therapy, stating it "reaches into the human body and removes a targeted bacterial species without touching anything else."
Although phage therapy is widely utilized in other countries, it remains unlicensed in the US, presenting a unique challenge and opportunity for its development.
[
Collection
]
[
|
...
]